Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study

Transfusion and Apheresis Science

Volumn 36, Issue 3, 2007, Pages 261-267

  Rombout Sestrienkova, Eva ^a   van Noord, Paulus A H ^a   van Deursen, Cees Th B M ^b   Sybesma, Bob J P H ^a   Nillesen Meertens, Ans E L ^a   Koek, Ger H ^c  

^a Sanquin Bloedbank Regio Zuidoost Nijmegen   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hereditary Hemochromatosis (HH); HFE gene; Phlebotomy; Therapeutic Erythrocytapheresis (TE)

Indexed keywords

FERRITIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST; CYTAPHERESIS; DISEASE COURSE; ERYTHROCYTAPHERESIS; FEMALE; HEMOCHROMATOSIS; HUMAN; INTERMETHOD COMPARISON; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; MALE; PATIENT SAFETY; PHLEBOTOMY; PILOT STUDY; TISSUE INJURY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; BLOOD COMPONENT REMOVAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOCHROMATOSIS; HUMANS; IRON OVERLOAD; MALE; MIDDLE AGED; PHLEBOTOMY; PILOT PROJECTS; RETROSPECTIVE STUDIES; THERAPEUTICS; TREATMENT OUTCOME;

EID: 34447633359     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.03.005     Document Type: Article

References (27)

1. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 (1996) 399-408
2. Risch N. Haemochromatosis, HFE and genetic complexity (letter). Nat Genet 17 (1997) 375-376
3. Burke W., Imperatore G., McDonnel S.M., Baron R.C., and Khoury M.J. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Gen Med 2 (2000) 271-277
4. Powell L.W., Subramaniam V.N., and Yapp T.R. Haemochromatosis in the new millennium. J Hepatol 32 (2000) 48-62
5. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., and Gelbart T. Penetrance of 845G > A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
6. Asberg A., Hveem K., Thorstensen K., Ellekjter E., Kannelonning K., Fjosne U., et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 36 (2001) 1108-1115
7. Marx J.J.M. Prevention in organ failure in hereditary haemochromatosis. Neth J Med 60 (2002) 419-422
8. Powel L.W. Hereditary hemochromatosis and iron overload diseases. J Gastroenterol Hepatol 17 (2002) S191-S195
9. Barton J.C., McDonnell S.M., Adams P.C., Brissot P., Powell L.W., et al. Management of hemochromatosis. Hemochromatosis management working group. Ann Intern Med 129 (1998) 932-939
10. Kirking H. Treatment of chronic iron overload. Clin Pharmacy 10 (1991) 775-783
11. Newman B.H. Blood donor complications after whole-blood donation. Curr Opin Hematol 11 (2004) 339-345
12. Jaquet Ph., Codaccioni J.L., Fabre M., and Marquier A. Accident mortel apres deux saignees au cours du traitement d' une hemochromatose. Diabete 15 (1967) 70-72
13. Hofstetter J.R. Dangers du traitement de l'hemochromatose par saignees. Gastroenterologia 87 (1957) 186-190
14. Kohan A., Niborski R., Daruich J., Rey J., Bastos F., Amerise G., et al. TE with recombinant human erythropoietin in hereditary hemochromatosis therapy:a new alternative. Vox Sang 79 (2000) 40-45
15. Valbonesi M., and Bruni R. Clinical application of therapeutic TE (TEA). Transfus Sci 22 (2000) 184-194
16. Waalen J., and Beutler E. Hereditary hemochromatosis:screening and management. Curr Hematol Rep 5 (2006) 34-40
17. Mariani R., Pellucchi S., Perseghin P., Corenghia Ch., and Piperno A. TE plus erythropoetin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 90 (2005) 717-718
18. Kellner H., and Zoller W.G. Repeated isovolemic large-volume TE in the treatment of idiopathic hemochromatosis. Z Gastroenterol 30 (1992) 779-783
19. Conte D., Mandelli C., Cesana M., Ferrini R., Marconi M., and Bianchi A. Effectiveness of TE in idiopathic hemochromatosis. Report of 14 cases. Int J Artif Organs 12 (1989) 59-62
20. Grima K.M. Therapeutic apheresis in hematological and oncological diseases. J Clin Apheresis 15 (2000) 28-52
21. Zoller W., Kellner H., and Spengel F.A. TE: a method for rapid extracorporeal elimination of erythrocytes. Results in 65 patients. Klin Wochenschr 88 (1988) 404-409
22. Rombout E., van Deursen C., Nillessen A., and van Noord P.A.H. Therapeutic arythrocytapheresis versus phlebotomy in hereditary hemochromatosis therapy: An ongoing study in a donor center. Transfus Apheresis Sci 33 (2005) 213
23. Cesana M., Mandelli C., Tiribelli C., Bianchi P.A., and Conte D. Concominant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine. Am J Gastroenterol 84 (1989) 150-152
24. Fraquelli M., Mandelli C., Cesarini L., Barisani D., Bianchi P.A., and Conte D. Survival and development of neoplasms in 56 patients with idiopathic hemochromatosis. Ann Ital Med Int 7 (1992) 26-29
25. Brittenham G.M. Disorders of iron metabolism: iron deficiency and overload. In: Hoffman R., Benz E.J., Shattil S.J., et al. (Eds). Hematology, basis principles and practice (1995), Churchill Livingstone, New York 492-523
26. Hicken B.L., Tucker D.C., and Barton J.C. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 98 9 (2003) 2072-2077
27. Popovsky M.A. Safety of RBC apheresis and whole blood donation in allogeneic and autologous blood donors. Transfus Apheresis Sci 34 (2006) 205-211